MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Depression"

  • MDS Virtual Congress 2020

    Prevalence, Impact, and Suboptimal Treatment of Depression in the Fox Insight Cohort

    R. Dobkin, M. Gara, S. Mann, K. Rodriguez, A. Interian (Piscataway, NJ, USA)

    Objective: Addressing unmet mental health needs in Parkinson’s disease (PD) requires delineating their scope and impact. This study evaluated (1) depressive symptom prevalence and treatment…
  • MDS Virtual Congress 2020

    Comparisons of motor and non-motor features between essential tremor with and without head tremor patiens

    J.X Peng, L. Wang, NN. Li, J.Y Li, L.R Duan, C.L Chen, R. Peng (Chengdu, China)

    Objective: We aimed to explore the motor and non-motor symptoms(NMS) especially cognitive and affective abnormalities of essential tremor (ET) with head tremor (ETh) and those without…
  • 2019 International Congress

    Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

    J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

    Objective: We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. Background: Depression occurs in ~50% of Parkinson’s disease (PD)…
  • 2019 International Congress

    The effects of zonisamide on motor and non-motor symptoms in patients with Parkinson’s disease: a 3-month open-label study

    K. Suzuki, H. Fujita, T. Matsubara, T. Kadowaki, K. Funakoshi, Y. Watanabe, T. Shiina, H. Sakuramoto, M. Hamaguchi, K. Hirata (Tochigi, Japan)

    Objective: To investigate the effect of zonisamide (ZNS) on motor and non-motor symptoms, such as depressive symptoms and sleep problems, in patients with Parkinson’s disease…
  • 2019 International Congress

    Higher levels of physical activity is associated with fewer non-motor symptoms in early Parkinson’s disease: a 1-year follow-up study

    S. Ng, N. Chia, M. Abbas, KY. Tay, WL. Au, EK. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the physical activity (PA) level in early Parkinson’s disease (PD) patients and its association with non-motor symptoms (NMS). Background: Lower PA is…
  • 2019 International Congress

    Vortioxetine treatment of depression in Parkinson’s disease

    M. Russo, C. Carrarini, F. Dono, L. Ferri, M. Di Pietro, M. Onofrj (Chieti, Italy)

    Objective: To assess efficacy and safety of Vortioxetine in Parkinson’s Disease (PD) patients affected by depression and its effects on motor performance. Background: Depression is…
  • 2019 International Congress

    Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

    Objective: The aim of this project was to evaluate high-fat diet (HFD) induced behavioral alterations in the A53T alpha-Synuclein Parkinsons’s disease mouse model. Background: Besides…
  • 2019 International Congress

    Influence of Cognitive Deficits and Tremor Severity of the Development of Depression in Nondemented Patients with Essential Tremor

    M. Petrova, O. Grigorova, M. Raycheva, L. Traykov (Sofia, Bulgaria)

    Objective: The aim of this study was to investigate the relationship between cognitive deficits and tremor severity with the development of depression in nondemented ET…
  • 2019 International Congress

    Neuropsychiatric manifestations in Parkinson’s disease

    O. Cherkaoui Rhazouani, N. Jalami, M. Chraa, N. Kissani (Marrakech, Morocco)

    Objective: Evaluate the different neuropsychiatric manifestations in Parkinson's disease. Background: Parkinson's disease (PD) is the second most common neurodegenerative pathology after Alzheimer's disease, although PD…
  • 2019 International Congress

    Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease

    SZ. Wei, F. Wang, CF. Liu (Suzhou, China)

    Objective: The aim of this study is to understand if the antidepressant effect of pramipexole is mediated by D2R or D3R in a mouse model…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley